• Media
  • All
  • Aevolve Responds to Millions of Alzheimer’s Patients Still Lacking Treatment to Slow the Disease


  • Home
  • All
  • Aevolve Responds to Millions of Alzheimer’s Patients Still Lacking Treatment to Slow the Disease

Aevolve Responds to Millions of Alzheimer’s Patients Still Lacking Treatment to Slow the Disease

As World Alzheimer’s Month draws to a close, excitement continues to grow in response to the bold vision of Aevolve — a new company using a blockchain investment platform to support innovative medical research designed to make a difference in the lives of millions of patients.

According to the World Health Organization, approximately 50 million people worldwide have dementia, a number growing by 10 million new cases every year. Alzheimer’s — a chronic neurodegenerative disease that cruelly robs individuals of their memory and has a damaging impact on their lifestyle in a variety of other ways — is the most common form of dementia and may contribute to 60 to 70 percent of all cases of dementia. Currently, there is no known cure or method of slowing the progression of this disease. While awaiting research that will deliver a cure or minimize its impact, there are currently a number of medications available to manage or stabilize the symptoms of Alzheimer’s, including memory loss and confusion, for a limited period.

Cholinesterase inhibitors are medications that block the normal breakdown of acetylcholine, the main neurotransmitter found in the body which has important functions in both the peripheral nervous system and the central nervous system. Medications in this category include Aricept®, Exelon®, Razadyne® and Namenda® (Memantine HCl), all of which have been approved by the U.S. Food and Drug Administration for the treatment of cognitive symptoms of Alzheimer’s disease, such as confusion, memory loss, and problems with reasoning and thinking.

Experienced physicians prescribe cholinesterase inhibitors to patients in the early to moderate stages of dementia related to Alzheimer’s disease to treat symptoms related to thought processes, including thinking, judgment, language, and memory.

According to the U.S. based Alzheimer’s Association, three commonly prescribed cholinesterase inhibitors are Donepezil (marketed under the brand name Ariceptâ), which is approved to treat all stages of Alzheimer’s disease; Galantamine (Razadyneâ) for mild-to-moderate stages; and Rivastigmine (Exelonâ) for mild-to-moderate Alzheimer’s disease.

For patients in the moderate to severe stages of Alzheimer’s disease, the U.S. Food and Drug Administration has approved Namendaâ (Memantine HCl) and a combination of Memantine and Donepezil (Namzaric®) for treatment. Memantine is prescribed as a drug treatment to aid patients in improving their memory, attention, reason, language, and ability to perform simple tasks.

The Alzheimer’s Association has noted that scientists have made notable headway in understanding how Alzheimer’s disease affects the brain, which in turn provides researchers with new insight into promising new drug treatments that may one day stop or slow down the progression of the disease.

Those following the latest developments in Alzheimer’s research are excited about Aevolve’s new marketplace and innovation platform, BioSpheres, which will support research through which patients with Alzheimer’s can have access to and receive approved treatment for the disease. BioSpheres will allow patients to be the first in line for groundbreaking treatments for cognitive symptoms at the moment they become available.

Taking the right medication is important in the care of individuals with Alzheimer’s disease. Because these drugs can only address some symptoms and may cause side effects, it is important for families and caregivers to clearly communicate with their doctors about every aspect of each patient’s treatment program including all the medications currently being taken, the purpose and proper usage of prescribed drugs, and additional measures to be followed in the care of these patients.

# # #

Aevolve is a protocol that supports medical innovations from R&D stages to full-scale commercialization, by connecting patients, investors, and scientific innovators. It offers Biospheres, an innovation marketplace that connects patients and the global community directly with scientific innovators and experts from all over the world to address various stages of the innovation life cycle. For more information, visit


Posted in:

All,  Health,  Innovations

Add comment

Your email address will not be published. Required fields are marked *

You might also like